News Releases

Printer friendly version

Protox To Present Prostate Cancer Data At ASCO Conference

Vancouver, British Columbia, February 13, 2008 – Protox Therapeutics Inc. (TSX: PRX), a leader in advancing novel, targeted therapeutic proteins, today announced that data from the completed Phase 1 clinical study testing PRX302 in patients with locally recurrent prostate cancer following radiation failure will be presented at the American Society of Clinical Oncology (“ASCO”) Genitourinary Cancer Symposium in San Francisco, California.

Scott Coffield, M.D., Principal Investigator from the lead site at Scott and White Memorial Hospital, will deliver the presentation, entitled "Intraprostatic Treatment of Patients with Locally Recurrent Prostate Cancer with the PSA-Activated Protoxin PRX302” on Thursday, February 14, 2008 at the San Francisco Marriott.

PRX302 is rationally designed to kill prostate cancer and hyperplastic cells that over-produce the enzyme prostate specific antigen (PSA). A Phase 1 study has been completed and final results were released in November 2007 indicating that PRX302 is safe and well tolerated while demonstrating encouraging signs of therapeutic activity. A Phase 2a clinical trial evaluating PRX302 for the treatment of localized recurrent prostate cancer following radiation failure has been initiated. The trial is designed to determine the optimal injection regimen that provides the maximal therapeutic benefit, while maintaining safety and tolerability of a single intra-prostatic treatment of PRX302. By increasing the volume and/or number of deposits, it is anticipated that the treatment effects of PRX302 may extend to larger volumes of the prostate and, consequently, enhance its therapeutic activity.

About Protox
Protox Therapeutics is a leader in advancing novel, targeted protein therapeutics for the treatment of cancer and other proliferative diseases. Two novel drug candidates derived from the company’s INxin™ and PORxin™ platforms are being developed in three clinical programs. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. A Phase 2a clinical trial evaluating PRX302 (PORxin) for the treatment of localized prostate cancer has been initiated and plans to commence a Phase 2 clinical trial for the treatment of benign prostatic hyperplasia (enlarged prostate) are currently underway.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

James Beesley
Director, Investor Relations
Protox Therapeutics
604-688-0199
jbeesley@protoxtherapeutics.com

Michael Moore
Investor Relations
The Equicom Group
416-815-0700 x 241
mmoore@equicomgroup.com